# Mondego Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mondego-bio

- Industry: Biotechnology
- Headquarters: Cantanhede, Portugal
- Website: www.mondegobio.com/
- Latest round: Series A (Sep 18, 2025)
- Investors on record: 3

## About

Mondego Bio, based in Portugal, specializes in the development of innovative immuno-oncology therapeutics, focusing on enhancing immune responses against tumors through targeted inhibition of specific pathways.Founded in Cantanhede, Portugal, Mondego Bio is dedicated to developing therapies targeting the JAK-STAT signaling pathway to improve cancer immunotherapy. The company has engaged in one investment deal, with its most recent funding occurring on September 18, 2025.Mondego Bio specializes in the development of Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) inhibitors, targeting the JAK-STAT signaling pathway. Their core product, a drug candidate identified as ZE00-0388, is designed to enhance immune response against tumors by inhibiting PTPN2, thereby improving the sensitivity and efficacy of immunotherapy regimens, particularly those utilizing interferon-gamma (IFN?). The product is currently in preclinical stages, with promising data reported at international scientific workshops and conferences. Mondego Bio primarily serves the oncology field, targeting healthcare providers and pharmaceutical companies looking to advance cancer immunotherapy solutions. The geographical markets for these products include Europe and North America, where significant research and clinical trial activities are concentrated.Mondego Bio's revenue model is structured around partnerships and collaborations with industry leaders and research institutions focused on cancer immunotherapy. The company engages in direct B2B transactions, collaborating with pharmaceutical firms that are interested in licensing or co-developing its PTPN2 inhibitor candidates. Transactions typically involve agreements for research and development funding, as well as milestone payments contingent upon achieving specific clinical and regulatory targets. The pricing structure, while not publicly disclosed, is expected to align with industry standards for innovative biopharmaceuticals, reflecting the complexity and potential of their flagship product, ZE00-0388, in the competitive oncology market. Through these strategic partnerships, Mondego Bio aims to secure the necessary funding to advance its drug candidates through the preclinical and clinical development phases.In September 2025, Mondego Bio raised an undisclosed amount of Series A funding led by new investor Biovance Capital Partners, with participation from new investors OrbiMed and Torrey Pines Investment. The company intends to utilize this funding to support the development and advancement of its product pipeline, focusing on launching their PTPN2 inhibitor candidate, ZE00-0388, into clinical trials. Mondego Bio is also planning to expand its market presence into additional regions, specifically targeting North America and parts of Europe, by 2026, to enhance its engagement with pharmaceutical partners and research institutions.

## Funding rounds

- Series A, Sep 18, 2025 — OrbiMed Advisors, Torrey Pines Investment, Biovance Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Torrey Pines Investment (https://capitalatlas.ai/funds/torrey-pines-investment) — Series A
- Biovance Capital (https://capitalatlas.ai/funds/biovance-capital) — Series A